Navigation Links
Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
Date:10/26/2008

WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two studies on SPI-256, a novel investigational HIV protease inhibitor (PI). One study based on an in vitro analysis demonstrates that the mode of interaction of SPI-256 with HIV protease provides a rationale for its high potency and high genetic barrier to resistance. The second study conducted in healthy volunteers demonstrates that SPI-256 is generally safe and well tolerated in humans and is amenable to boosting by pharmacokinetic enhancers (PKEs). The data were presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual Infectious Diseases Society of America (IDSA) joint meeting held in Washington, D.C.

"Two ongoing significant needs in contemporary HIV therapy are: new agents that have activity against mutant virus and also have a high genetic barrier to developing resistance; and new agents that can boost the pharmacokinetic levels of existing drugs," said Martin Markowitz, MD, professor and clinical director at the Aaron Diamond AIDS Research Center. "These data on SPI-256 look very promising and address the need for new agents with activity against protease inhibitor-resistant virus as well as the development of resistance. I look forward to further advancements and innovations in HIV that will address our needs in the treatment community from a resistance, as well as a PK, point of view."

Data on SPI-256 at this conference

Discovery and in vitro activity of SPI-256

Scientists from Sequoia Pharmaceuticals presented their structure-based approach that led to the development of SPI-256. Prior to discovering SPI-256, Sequoia scientists examined three-dimensional structures of wild-type and drug-resistant mutant HIV proteases bound to selected inhibitors. By analyzing these structures, the Sequoia scientists were able to identify a subset of main-chain and active-site atoms of
'/>"/>

SOURCE Sequoia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... 23, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ... integrated healthcare enterprise, today announced that the Group has accumulated ... Corporation ("CCBC," - CO.US) from the open market between December ... Group now owns 39.5% of the issued share capital of ...
... Four hospitals serving Virginia patients reduced healthcare-acquired infection rates ... in savings of $1.2 million in additional costs to ... plan to existing federal hand washing protocols, these hospitals ... and reduced patient length-of-stay and unnecessary readmissions. ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... 28, 2014 Dr. Andrew Campbell, one ... announced the expansion of Quintessa Aesthetic Center into a ... located at W307 N1497 Golf Road in Suite 200 ... Dr. Campbell, the new Delafield location will offer a ... patients, including: Botox, filler injectables , micro laser ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic surgeons ... for those in the area that would like to learn more ... will take place on December 11, 2014, from 6:00 p.m. until ... Houston at 4208 Richmond Ave. , “We want to wish ... and celebrate the season with us on December 11, 2014 from ...
(Date:11/28/2014)... Evergreen, Colorado (PRWEB) November 28, 2014 Written ... Jackson , Brook Forest Voices releases the “The Happiest ... audiobook , a compelling account of how and why Project ... of Idaho by his mother Josie and the Reverend Richard ... millionaire by the age of 30, but realized that he ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... , , WEDNESDAY, April 22 (HealthDay News) -- Responding to ... Administration said Wednesday that it will now allow 17-year-olds ... a doctor,s prescription. , In 2006, the FDA ... also known as Plan B, to women 18 and ...
... 22 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... New Jersey based company focused on clinical approval of ... disc replacement device. This strategic acquisition allows NuVasive the ...
... TMK ) reported today that for the quarter ... (after a charge of $.49 per share for impairment of ... quarter. Net operating income for the quarter was $1.49 ... per share for the year-ago quarter. Reconciliations between net income ...
... of drinking while pregnant, , , WEDNESDAY, April 22 (HealthDay ... and mental problems in babies born to women who ... known that drinking while pregnant can be harmful to ... to children with noticeable deficits, noted Chris Downing, a ...
... AMICAS, Inc. (Nasdaq: AMCS ), a ... solutions, today announced it will report the company,s financial ... after the market closes on Monday, May 11, 2009.(Logo: ... of its financial results, management will host a conference ...
... To Webcast Annual Shareholders MeetingLIONVILLE, Pa., April 22 ... announced today that it will release 2009 first quarter ... 30, 2009, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ...
Cached Medicine News:Health News:FDA Approves 'Plan B' Pill for 17-Year-Olds 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 2Health News:Torchmark Corporation Reports First Quarter 2009 Results 3Health News:Torchmark Corporation Reports First Quarter 2009 Results 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 5Health News:Torchmark Corporation Reports First Quarter 2009 Results 6Health News:Torchmark Corporation Reports First Quarter 2009 Results 7Health News:Torchmark Corporation Reports First Quarter 2009 Results 8Health News:Torchmark Corporation Reports First Quarter 2009 Results 9Health News:Torchmark Corporation Reports First Quarter 2009 Results 10Health News:Torchmark Corporation Reports First Quarter 2009 Results 11Health News:Torchmark Corporation Reports First Quarter 2009 Results 12Health News:AMICAS Schedules First Quarter 2009 Earnings Results Conference Call 2Health News:West to Host 2009 First Quarter Conference Call 2
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
... wide orifice tip, the Finntip Wide is ... and macromolecules like genomic DNA. This tip ... fragmentation. It is excellent for use with ... the inside diameter of the orifice is ...
... designed to optimize the accuracy and precision ... products is widely recognized by customers throughout ... extended over the years and now covers ... tips including filter tips, certified pure tips, ...
... plastic-wrapped racks of 96 tips, Sterilized Diamond- ... autoclave. Sterilized Diamond Tips are irradiated by ... delivered with a certificate of sterilization, specifying ... are certified free of detectable Rnase, Dnase, ...
Medicine Products: